These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 26417929)

  • 1. Cytotoxic T cell responses are enhanced by antigen design involving the presentation of MUC1 peptide on cholera toxin B subunit.
    Lu W; Qiu L; Yan Z; Lin Z; Cao M; Hu C; Wang Z; Wang J; Yu Y; Cheng X; Cao P; Li R
    Oncotarget; 2015 Oct; 6(33):34537-48. PubMed ID: 26417929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1.
    Pietersz GA; Li W; Osinski C; Apostolopoulos V; McKenzie IF
    Vaccine; 2000 Apr; 18(19):2059-71. PubMed ID: 10706970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced induction of anti-tumor CTLs in vitro by a lentivirus-transduced dendritic cell vaccine expressing secondary lymphoid tissue chemokine and mucin 1.
    Wang B; Zhu Y; Zhang JJ; Chen Z; Liang WB; Xu ZK
    Asian Pac J Cancer Prev; 2011; 12(11):2811-7. PubMed ID: 22393946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats.
    Zhang S; Zhang H; Shi H; Yu X; Kong W; Li W
    Hum Immunol; 2008; 69(4-5):250-8. PubMed ID: 18486759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of a Tripartite Cell Penetrating Peptide Containing a MUC1 Variable Number of Tandem Repeat (VNTR) and A T Helper Epitope.
    Brooks N; Hsu J; Esparon S; Pouniotis D; Pietersz GA
    Molecules; 2018 Sep; 23(9):. PubMed ID: 30200528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.
    Lakshminarayanan V; Thompson P; Wolfert MA; Buskas T; Bradley JM; Pathangey LB; Madsen CS; Cohen PA; Gendler SJ; Boons GJ
    Proc Natl Acad Sci U S A; 2012 Jan; 109(1):261-6. PubMed ID: 22171012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of a cholera toxin B subunit (CTB) and human mucin 1 (MUC1) conjugate protein in a MUC1-tolerant mouse model.
    Pinkhasov J; Alvarez ML; Pathangey LB; Tinder TL; Mason HS; Walmsley AM; Gendler SJ; Mukherjee P
    Cancer Immunol Immunother; 2010 Dec; 59(12):1801-11. PubMed ID: 20824430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heat shock fusion protein induces both specific and nonspecific anti-tumor immunity.
    Li D; Li H; Zhang P; Wu X; Wei H; Wang L; Wan M; Deng P; Zhang Y; Wang J; Liu Y; Yu Y; Wang L
    Eur J Immunol; 2006 May; 36(5):1324-36. PubMed ID: 16619287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
    Soares MM; Mehta V; Finn OJ
    J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model.
    Mukherjee P; Pathangey LB; Bradley JB; Tinder TL; Basu GD; Akporiaye ET; Gendler SJ
    Vaccine; 2007 Feb; 25(9):1607-18. PubMed ID: 17166639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs.
    Wang Y; Liu C; Xia Q; Wang P; Li B; Lu Z; Sun J; Wu H; Yu B; Wu J; Yu X; Kong W; Zhang H; Cong X
    Oncol Rep; 2014 Mar; 31(3):1437-44. PubMed ID: 24378623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses.
    Barratt-Boyes SM; Vlad A; Finn OJ
    Clin Cancer Res; 1999 Jul; 5(7):1918-24. PubMed ID: 10430099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
    Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
    Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine.
    Rong Y; Jin D; Wu W; Lou W; Wang D; Kuang T; Ni X; Qin X
    BMC Cancer; 2009 Jun; 9():191. PubMed ID: 19534821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines.
    Liu Y; Wang Z; Yu F; Li M; Zhu H; Wang K; Meng M; Zhao W
    Int J Nanomedicine; 2021; 16():403-420. PubMed ID: 33469292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel multi-epitope peptide vaccine against cancer: an in silico approach.
    Nezafat N; Ghasemi Y; Javadi G; Khoshnoud MJ; Omidinia E
    J Theor Biol; 2014 May; 349():121-34. PubMed ID: 24512916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment.
    Mukherjee P; Ginardi AR; Madsen CS; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ
    Glycoconj J; 2001; 18(11-12):931-42. PubMed ID: 12820727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CpG ODN1826 as a Promising Mucin1-Maltose-Binding Protein Vaccine Adjuvant Induced DC Maturation and Enhanced Antitumor Immunity.
    Jie J; Zhang Y; Zhou H; Zhai X; Zhang N; Yuan H; Ni W; Tai G
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29558459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice.
    Yang M; Yan Y; Fang M; Wan M; Wu X; Zhang X; Zhao T; Wei H; Song D; Wang L; Yu Y
    Int Immunopharmacol; 2012 Aug; 13(4):408-16. PubMed ID: 22595192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.